Dr. Reddy’s debuts generic Revlimid

Dr. Reddy’s is introducing lenalidomide capsules, a generic of Revlimid.

With this volume-limited launch, Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5-mg and 20-mg strengths.

Revlimid is used to treat adults with multiple myeloma in combination with the medicine dexamethasone or as maintenance treatment after autologous hematopoietic stem cell transplantation, a type of stem cell transplant that uses your own stem cells.

[Read more: Dr. Reddy's intros OTC Allegra-D]

“We are pleased with the first-to-market launch of two of our six strengths of lenalidomide capsules with 180-day market exclusivity,” said Marc Kikuchi, CEO of North America generics at Dr. Reddy’s. “Bringing a more affordable generic version to market creates greater patient access for this important drug.”

As previously announced, Celgene agreed to provide Dr. Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the United States in settlement of all outstanding claims of its litigation. The agreed-upon percentages remain confidential. As part of the settlement, Dr. Reddy’s also is licensed to sell generic lenalidomide capsules in the United States without volume limitation, beginning Jan. 31, 2026.

[Read more: Dr. Reddy's intros generic Revlimid in Canada]

Dr. Reddy’s lenalidomide capsules are available in strengths of 2.5 mg, 5 mg and 10 mg, each in a bottle-count size of 28, as well as 15-mg, 20-mg and 25-mg strengths, each in a bottle-count size of 21.